Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric ...

(Operator Instructions) Good morning, and thank you for joining us. Earlier today, Allurion Technologies Inc., Issued a press release announcing financial results for the quarter ended December 31 ...

If a stockholder has any questions about submitting a proxy or requires assistance, please contact Innisfree M&A Incorporated, Allurion’s proxy solicitor, toll-free at (877) 750-9499 or collect at ...

Allurion Technologies, Inc. (ALUR) came out with a quarterly loss of $7 per share versus the Zacks Consensus Estimate of a loss of $5. This compares to loss of $15.75 per share a year ago.

NATICK, Mass., April 03, 2025--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that its Special Meeting of ...

Good morning, and thank you all for joining us. Earlier today, Allurion Technologies Inc. issued a press release announcing financial results for the quarter ended December 31st, 2024 and provided ...

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, a swallowable and procedure-less ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...